BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary Delivery of Biological Drugs. Pharmaceutics 2020;12:E1025. [PMID: 33114726 DOI: 10.3390/pharmaceutics12111025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Mahar R, Chakraborty A, Nainwal N. The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers. Journal of Drug Delivery Science and Technology 2022;76:103759. [DOI: 10.1016/j.jddst.2022.103759] [Reference Citation Analysis]
2 Pitiot A, Heuzé-vourc’h N, Sécher T. Alternative Routes of Administration for Therapeutic Antibodies—State of the Art. Antibodies 2022;11:56. [DOI: 10.3390/antib11030056] [Reference Citation Analysis]
3 Owen MJ, Celik U, Chaudhary SK, Yik JHN, Patton JS, Kuo M, Haudenschild DR, Liu G. Production of Inhalable Ultra-Small Particles for Delivery of Anti-Inflammation Medicine via a Table-Top Microdevice. Micromachines 2022;13:1382. [DOI: 10.3390/mi13091382] [Reference Citation Analysis]
4 Weißenborn L, Richel E, Hüseman H, Welzer J, Beck S, Schäfer S, Sticht H, Überla K, Eichler J. Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Miniprotein. Int J Mol Sci 2022;23:6309. [PMID: 35682988 DOI: 10.3390/ijms23116309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hersey S, Keller S, Mathews J, King L, Bandukwala A, Berisha F, Birchler M, Bower J, Clausen V, Duarte J, Garofolo F, Hopper S, Kar S, Mabrouk O, Marshall JC, McGuire K, Naughton M, Saito Y, Schuhmann I, Sperinde G, Teixeira P, Vitaliti A, Wang YM, Wnek R, Zhang Y, Spitz S, Decman V, Eck S, Estevam J, Goihberg P, Alcaide EG, Gonneau C, Hedrick MN, Hopkins G, Junker F, Nuti S, Sommer U, Standifer N, Stevens C, Stevens E, Hendricks C, Wadhwa M, Torri A, Ma M, Harris S, Kumar S, Partridge MA, Caiazzo T, Chilewski S, Cludts I, Coble K, Gorovits B, Grimaldi C, Jordan G, Kamerud J, Leary B, Liang M, Lim H, Mayer A, O'Connor E, Palackal N, Poetzl J, Prior S, Abhari MR, Savoie N, Soo C, Ware M, Wu B, Xu Y, Yang TY, Zoghbi J. 2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2 - Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation). Bioanalysis 2022. [PMID: 35578974 DOI: 10.4155/bio-2022-0080] [Reference Citation Analysis]
6 Tai W, Kwok PCL. Recent advances in drug delivery to the central nervous system by inhalation. Expert Opin Drug Deliv 2022. [PMID: 35532357 DOI: 10.1080/17425247.2022.2074975] [Reference Citation Analysis]
7 Hasan M, Khatun A, Kogure K. Iontophoresis of Biological Macromolecular Drugs. Pharmaceutics 2022;14:525. [DOI: 10.3390/pharmaceutics14030525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Stegemann S, Faulhammer E, Pinto JT, Paudel A. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance. Int J Pharm 2022;614:121445. [PMID: 34998921 DOI: 10.1016/j.ijpharm.2021.121445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Bartels M, van Osdol W, Le Merdy M, Chappelle A, Kuhl A, West R. In silico predictions of absorption of MDI substances after dermal or inhalation exposures to support a category based read-across assessment. Regul Toxicol Pharmacol 2022;129:105117. [PMID: 35017021 DOI: 10.1016/j.yrtph.2022.105117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hufnagel S, Sahakijpijarn S, Moon C, Cui Z, Williams Iii RO. The Development of Thin-film Freezing and Its Application to Improve Delivery of Biologics as Dry Powder Aerosols. KONA. [DOI: 10.14356/kona.2022010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
11 Anderson S, Atkins P, Bäckman P, Cipolla D, Clark A, Daviskas E, Disse B, Entcheva-Dimitrov P, Fuller R, Gonda I, Lundbäck H, Olsson B, Weers J. Inhaled Medicines: Past, Present, and Future. Pharmacol Rev 2022;74:48-118. [PMID: 34987088 DOI: 10.1124/pharmrev.120.000108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
12 Wang X, Xie Z, Zhao J, Zhu Z, Yang C, Liu Y. Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections. Front Cell Infect Microbiol 2021;11:758392. [PMID: 34938668 DOI: 10.3389/fcimb.2021.758392] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Tang W, Zhang Y, Zhu G. Pulmonary delivery of mucosal nanovaccines. Nanoscale 2021. [PMID: 34918733 DOI: 10.1039/d1nr06512b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 García-Fernández A, Sancenón F, Martínez-Máñez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev 2021;177:113953. [PMID: 34474094 DOI: 10.1016/j.addr.2021.113953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Xiao Y, Tang Z, Huang X, Joseph J, Chen W, Liu C, Zhou J, Kong N, Joshi N, Du J, Tao W. Glucose-responsive oral insulin delivery platform for one treatment a day in diabetes. Matter 2021;4:3269-85. [DOI: 10.1016/j.matt.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shen Z, Xiang Y, Vergara S, Chen A, Xiao Z, Santiago U, Jin C, Sang Z, Luo J, Chen K, Schneidman-Duhovny D, Camacho C, Calero G, Hu B, Shi Y. A resource of high-quality and versatile nanobodies for drug delivery. iScience 2021;24:103014. [PMID: 34522857 DOI: 10.1016/j.isci.2021.103014] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynié L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun 2021;12:5469. [PMID: 34552091 DOI: 10.1038/s41467-021-25480-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
18 Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm Sin B 2021;11:2565-84. [PMID: 34522598 DOI: 10.1016/j.apsb.2021.05.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Najmeddin A, Shapourabadi MB, Behdani M, Dorkoosh F. Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view. Biochim Biophys Acta Gen Subj 2021;:129974. [PMID: 34343644 DOI: 10.1016/j.bbagen.2021.129974] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Hickey AJ, Stewart IE. Inhaled antibodies: Quality and performance considerations. Hum Vaccin Immunother 2021;:1-10. [PMID: 34191682 DOI: 10.1080/21645515.2021.1940650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Benke E, Varga P, Szabó-Révész P, Ambrus R. Stability and In Vitro Aerodynamic Studies of Inhalation Powders Containing Ciprofloxacin Hydrochloride Applying Different DPI Capsule Types. Pharmaceutics 2021;13:689. [PMID: 34064698 DOI: 10.3390/pharmaceutics13050689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chang RYK, Chow MYT, Khanal D, Chen D, Chan HK. Dry powder pharmaceutical biologics for inhalation therapy. Adv Drug Deliv Rev 2021;172:64-79. [PMID: 33705876 DOI: 10.1016/j.addr.2021.02.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
23 Zhang Y, Davis DA, AboulFotouh K, Wang J, Williams D, Bhambhani A, Zakrewsky M, Maniruzzaman M, Cui Z, Williams RO 3rd. Novel formulations and drug delivery systems to administer biological solids. Adv Drug Deliv Rev 2021;172:183-210. [PMID: 33705873 DOI: 10.1016/j.addr.2021.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
24 Lo JCK, Pan HW, Lam JKW. Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl-β-Cyclodextrin as Excipient. Pharmaceutics 2021;13:615. [PMID: 33923196 DOI: 10.3390/pharmaceutics13050615] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
25 Vllasaliu D. Non-Invasive Drug Delivery Systems. Pharmaceutics 2021;13:611. [PMID: 33922587 DOI: 10.3390/pharmaceutics13050611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fröhlich E, Salar-Behzadi S. Oral inhalation for delivery of proteins and peptides to the lungs. Eur J Pharm Biopharm 2021;163:198-211. [PMID: 33852968 DOI: 10.1016/j.ejpb.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
27 Simpson I. Industry Update covering November 2020. Ther Deliv 2021;12:183-9. [PMID: 33624539 DOI: 10.4155/tde-2021-0002] [Reference Citation Analysis]
28 Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. bioRxiv 2021:2021. [PMID: 33655253 DOI: 10.1101/2021.02.23.432569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
29 Matera MG, Calzetta L, Ora J, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opin Drug Deliv 2021;18:891-906. [PMID: 33412922 DOI: 10.1080/17425247.2021.1873271] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Vishwa B, Moin A, Gowda DV, Rizvi SMD, Hegazy WAH, Abu Lila AS, Khafagy ES, Allam AN. Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis. Pharmaceutics 2021;13:79. [PMID: 33430162 DOI: 10.3390/pharmaceutics13010079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]